NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 13 hours 29 min ago

Innovative Mental Health Services Research Not Involving Clinical Trials (R01)

Fri, 04/28/2017 - 11:28
Funding Opportunity PAR-17-264 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research (see http://www.nimh.nih.gov/about/strategic-planning-reports/strategic-research-priorities/srp-objective-4/index.shtml).
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (U01)

Fri, 04/28/2017 - 03:07
Funding Opportunity RFA-HL-17-034 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications, from investigators with active U01 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R24)

Fri, 04/28/2017 - 03:07
Funding Opportunity RFA-HL-17-030 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications, from investigators with active R24 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R01)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-029 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications, from investigators with active R01 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (UM2)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-031 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active UM2 Program Project or Center with Complex Structure Cooperative Agreement awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P50)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-032 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active P50 specialized center awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (UM1)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-026 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite invites revision applications, from investigators with active UM1 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P41)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-033 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active P41 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (U54)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-025 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active U54 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (U24)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-028 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications, from investigators with active U24 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (UC4)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-027 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications, from investigators with active UC4 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R41/R42)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-024 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active R41/R42 Small Business Technology Transfer (STTR) Grant awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R43/R44)

Fri, 04/28/2017 - 03:06
Funding Opportunity RFA-HL-17-023 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active R43/R44 Small Business Innovation Research Grants (SBIR) awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Categories: NIH-Funding

Notice of Change to Key Dates for PAR-16-021 "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)"

Thu, 04/27/2017 - 13:19
Notice NOT-HL-17-510 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Change in the Expiration Date for PA-14-316 "Obesity and Asthma: Awareness and Self- Management (R01)"

Thu, 04/27/2017 - 10:20
Notice NOT-NR-17-011 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice to Extend the Expiration Date for PA-14-068 "Neurobiology of Migraine (R01)"

Thu, 04/27/2017 - 09:59
Notice NOT-NS-17-027 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

New "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018

Thu, 04/27/2017 - 09:42
Notice NOT-OD-17-062 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding